Afuco™ Anti-Human Chemokine ADCC Recombinant Antibody (E6011), ADCC Enhanced (CAT#: AFC-154CL)

Figure 1 The primary reasons given for leaving the study were the subjects’choice (two subjects; 5.4%),AEs (two subjects; 5.4%),or disease progression (one subject; 2.7%).

Mean (+ standard deviation, SD) serum E6011 concentration time course by dose.

Tanaka, Y., Takeuchi, T., Umehara, H., Nanki, T., Yasuda, N., Tago, F., ... & Imai, T. (2018). Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. Modern rheumatology, 28(1), 58-65.

Figure 2 Tender and swollen joint counts decreased following 12 weeks of E6011 treatment in all groups compared to baseline values.

(a) Mean change in tender (68)/swollen (66) joint count from baseline to week 12 (LOCF). (b) Bar chart of the ACR response rate at week 12 (NRI). (c) Stacked bar chart of DAS28-ESR by EULAR response criteria at week 12 (NRI). (d) Stacked bar chart showing disease activity of DAS28-ESR at week 12 (NRI). LOCF: last observation carried forward; NRI: nonresponder imputation.

Tanaka, Y., Takeuchi, T., Umehara, H., Nanki, T., Yasuda, N., Tago, F., ... & Imai, T. (2018). Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. Modern rheumatology, 28(1), 58-65.

Figure 3 Time profile of E6011, Total FKN and soluble FKN modulation pattern.

The circles represent the arithmetic mean of the observed data, and the error bars represent the standard deviation. E6011, n = 19.Total FKN, n = 15.There were no observable data in the 0.05mg/kg group for total FKN concentration.(B) Human. Lines represent typical predicted (population mean)time course.(C) Human. Circles represent the arithmetic mean of the observed data, and the error bars represent the standard deviation. E6011, n = 36. Total FKN, n = 64.There were no observable data in the 0.0006 and 0.006mg/kg groups for E6011 concentration.

Tabuchi, H., Katsurabara, T., Mori, M., Aoyama, M., Obara, T., Yasuda, N., ... & Kumagai, Y. (2018). Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study. The Journal of Clinical Pharmacology.